Related Experiment Videos
Aromatase expression in ovarian epithelial cancers
S Cunat1, F Rabenoelina, J-P Daurès
1Laboratoire de Biologie Cellulaire et Hormonale, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France. s-cunat@chu-montpellier.fr
Summary
Aromatase (CYP19) is expressed in normal ovarian tissues and some ovarian cancers, suggesting potential estrogen responsiveness and a basis for using aromatase inhibitors (AIs) to treat certain ovarian cancers.
Area of Science:
- Endocrinology and Reproductive Biology
- Molecular Biology
- Oncology
Background:
- Aromatase (CYP19) plays a key role in estrogen biosynthesis.
- Understanding aromatase expression in ovarian tissues is crucial for gynecological cancer research.
Purpose of the Study:
- To investigate aromatase mRNA and protein expression in normal and cancerous ovarian epithelial cells and tissues.
- To evaluate the effects of aromatase inhibitors on ovarian cancer cell lines.
Main Methods:
- Real-time PCR for mRNA expression analysis.
- Immunohistochemistry (IHC) for protein localization.
- Tritiated water assay for enzyme activity.
- Treatment with third-generation aromatase inhibitors (letrozole, exemestane).
Main Results:
- Aromatase mRNA was detected in human ovarian surface epithelial cells and some ovarian cancer cell lines (BG1, PEO4, PEO14), but not others (SKOV3, NIH:OVCAR-3).
- Aromatase expression was significantly higher in normal ovaries and cysts compared to ovarian cancers.
- Aromatase was predominantly localized to the epithelium in normal ovarian tissues.
- An inverse correlation was observed between aromatase and ERalpha expression.
- Aromatase inhibitors (letrozole, exemestane) inhibited aromatase activity and exhibited antiproliferative effects on estrogen-responsive BG1 cells.
Conclusions:
- Aromatase is expressed in normal ovarian epithelium and in a subset of ovarian cancers.
- The presence of aromatase suggests that some ovarian tumors may be estrogen-dependent.
- Aromatase inhibitors show potential as a therapeutic strategy for a subgroup of ovarian epithelial cancers.